GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cutera Inc (NAS:CUTR) » Definitions » Cash Ratio

Cutera (Cutera) Cash Ratio : 1.94 (As of Sep. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Cutera Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Cutera's Cash Ratio for the quarter that ended in Sep. 2023 was 1.94.

Cutera has a Cash Ratio of 1.94. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Cutera's Cash Ratio or its related term are showing as below:

CUTR' s Cash Ratio Range Over the Past 10 Years
Min: 0.37   Med: 1.92   Max: 4.57
Current: 1.94

During the past 13 years, Cutera's highest Cash Ratio was 4.57. The lowest was 0.37. And the median was 1.92.

CUTR's Cash Ratio is ranked better than
62.73% of 856 companies
in the Medical Devices & Instruments industry
Industry Median: 1.25 vs CUTR: 1.94

Cutera Cash Ratio Historical Data

The historical data trend for Cutera's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cutera Cash Ratio Chart

Cutera Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.75 0.58 0.87 2.22 3.00

Cutera Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.55 3.00 2.46 2.16 1.94

Competitive Comparison of Cutera's Cash Ratio

For the Medical Devices subindustry, Cutera's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cutera's Cash Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cutera's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Cutera's Cash Ratio falls into.



Cutera Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Cutera's Cash Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash Ratio (A: Dec. 2022 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=317.314/105.839
=3.00

Cutera's Cash Ratio for the quarter that ended in Sep. 2023 is calculated as:

Cash Ratio (Q: Sep. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=179.516/92.406
=1.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cutera  (NAS:CUTR) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Cutera Cash Ratio Related Terms

Thank you for viewing the detailed overview of Cutera's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cutera (Cutera) Business Description

Traded in Other Exchanges
Address
3240 Bayshore Boulevard, Brisbane, CA, USA, 94005
Cutera Inc is a medical device company. It specializes in the design, development, manufacture, marketing and servicing of laser and other energy based aesthetics systems for practitioners internationally. Its products include enlighten, excel HR, excel V, Xeo and Trusculpt 3D among others. The company markets and sells its products under the trademarks such as Cutera, Acutip, Coolglide, Enlighten, Excel HR, Excel V, Genesis plus, Pico-genesis, Titan, Trusculpt, and Xeo among others. It derives the majority of its revenue from the United States geographic segment.
Executives
Taylor C. Harris director 6035 STONERIDGE DRIVE, PLEASANTON CA 94588
Stuart Drummond officer: Interim Chief Financial Office C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE CA 94005
Jeffrey S Jones officer: Chief Operating Officer C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
Kevin J Cameron director C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Nicholas Sheridan Lewin director 3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Keith J Sullivan director C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
David H Mowry director, officer: Chief Executive Officer 9775 TOLEDO, IRVINE CA 92618
Rohan Seth officer: Chief Financial Officer C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE CA 94005
Timothy J Oshea director C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE CA 94005
Juliane Park director C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE CA 94005
Janet D. Widmann director 1411 E. MISSION AVENUE, SPOKANE WA 99202
J Daniel Plants director ONE EMBARCADERO CENTER, SUITE 1140, SAN FRANCISCO CA 94111
Katherine S Zanotti director 431 E 9TH STREET, HINSDALE IL 60521
Joseph E Whitters director
Sheila Hopkins director C/O WARNACO INC, 90 PARK AVENUE, NEW YORK NY 10016

Cutera (Cutera) Headlines

From GuruFocus